Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/rilpivirine in the United States, 2021–2023

While CAB/RPV uptake is increasing, its use remains modest and uneven. High rates of virologic suppression support its real-world effectiveness, but disparities by age, region, and payer point to persistent barriers. Continued real-world monitoring and targeted implementation strategies are critical to fully realizing the potential of long-acting injectable ART.